New Technology– category –
-
LNP-Delivered Multi-Specific CAR mRNA Engineering Platform Advances: Enables Controllable In Vivo CAR Expression, Overcomes Autologous Cell Manufacturing Challenges
Ace Therapeutics Unknown Overview A lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) therapy platform is advancing as a novel strategy to generate CAR-expressing immune cells in vivo. This approach allows for transient and contro... -
Insilico Medicine’s AI-Driven Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Advanced Mesothelioma, Accelerating Development
Insilico Medicine Press Release USA Overview Insilico Medicine announced that its AI-driven pan-TEAD inhibitor, ISM6331, developed using the Chemistry42 platform, received Fast Track Designation from the FDA for advanced malignant pleura... -
LNP-Mediated Gene Therapy to Correct ACTA2 Mutations Shows Promise: Reduces Stroke-Related Mortality, Offers Re-dosability & Lower Costs Over Viral Vectors
MSMDS.org USA Overview A novel lipid nanoparticle (LNP)-based gene therapy strategy is under development to correct ACTA2 mutations in vascular smooth muscle cells. This approach offers significant advantages over viral vectors, includin... -
FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation
Journal of Medicinal Chemistry - ACS Publications USA Overview On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated fo... -
Eli Lilly’s Triple Agonist Retatrutide Achieves 21-23% Weight Loss in Diabetic and CVD Patients Over 80 Weeks, Nears FDA Submission
BioPharma Dive USA Overview Eli Lilly is preparing to seek FDA approval for its obesity drug retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors. New data from the Triumph-2 and Triumph-3 studies showed average bod... -
AI Drug Discovery Reshapes Early Pharma Pipeline: Accelerates Target ID & Hit Generation to De-risk Late-Stage Failures
Converge Bio Unknown Overview AI-driven drug discovery is primarily impacting the early stages of the pharmaceutical pipeline, such as target identification and hit generation, by significantly accelerating processes that traditionally r... -
AI Drug Development Shifts to Clinical Validation Efficiency with Over 170 AI-Designed Molecules in Trials
Biology Digital News Unknown Overview The AI-driven pharmaceutical sector is reorienting its strategy from rapid drug discovery to enhancing clinical validation efficiency and pipeline quality, with over 170 AI-designed molecules now in ... -
AI-Designed Drugs Achieve 80-90% Phase 1 Success in Lung Cancer, Doubling Market Entry Probability
OncLive USA Overview AI-designed drugs are exhibiting remarkably high Phase 1 success rates of 80-90%, potentially doubling the probability of market entry compared to historical benchmarks. In lung cancer, AI tools show early promise ac... -
AI Accelerates Next-Gen Drug Design: From De Novo Protein Creation to Optimized Clinical Trials
SiTech Blog (MIT Technology Review analysis) USA Overview Artificial intelligence is revolutionizing drug discovery by enhancing every stage from protein structure prediction to clinical trial optimization. Generative models like RFdiffu... -
French ITEN Launches “SOLIMED” Project for High-Capacity Solid-State Batteries in Class III Implantable Medical Devices: Targeting 600Wh/L and 20-Minute Fast Charging
Power Electronics News France Overview French solid-state energy storage company ITEN announced "SOLIMED," a major development program under Europe's IPCEI Tech4Cure initiative, to adapt high-capacity solid-state battery technology for C...
